



Heart Failure Society of America (HFSA) 2023 Annual Scientific Meeting

October 6 – October 9, 2023; Cleveland, OH; Resource Hub – Draft

Welcome to our resource hub for Heart Failure Society of America Annual Scientific Meeting 2023 (HFSA)! This is a one-stop-shop for all your HFSA 2023 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Important Conference Information. The HFSA Annual Scientific Meeting 2023 is a meeting where heart failure science, research, and practical management will be shared, and also provides many networking and connection opportunities.

Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Diabetes Therapy Highlights](#)

[Exhibit Hall](#)

[Previous HFSA Coverage on CCKB](#)

Useful Conference Links

1. [Conference Website](#)
2. [Conference Registration](#)
3. [Day-by-Day Conference Preview](#)
4. [Conference Program](#)

Day-of Conference Reports

1. [HFSA Day #1 Highlights](#)
2. [HFSA Day #2-3 Highlights](#)
3. [HFSA Day #4 Highlights](#)

Diabetes Therapy Highlights

1. [Prof. Laura Peters, Ms. Megan Fraser, Ms. Mary Conti, and Ms. Sharon Huerta](#) present on the importance of engagement with cardiovascular team clinicians in clinical research and quality improvement
2. [Dr. Sawhney presents data](#) showing no correlation between cardiology consultations and prescription of SGLT-2 inhibitors in HF patients
3. [HFSA 2023 features >50 exhibitors](#) and the first of seven oral abstract and ePoster hub sessions
4. [Panel discusses the implementation of SGLT-2s](#) in clinical practice for heart failure patients with HFpEF, HFmrEF, and HFrEF
5. [Dr. Biykem Bozkurt \(Baylor University\)](#) speaks to the unmet needs in implementing GDMT for HFrEF
6. [The EMPULSE trial](#): Dr. John Teerlink (University of California San Francisco) affirms the efficacy of SGLT-2s for hospitalized HF patients, regardless of left ventricular ejection fraction (LVEF)
7. [PRESERVED-HF study](#) reveals that SGLT-2 inhibitors have no effect on metabolite clusters in HFpEF patients, in contrast with HFrEF patients

8. [Diverse panel shares insights on patient reported outcomes](#), their challenges in implementation, and future directions for improvement
9. [Dr. Ankeet Bhatt \(Kaiser San Francisco Medical Center\) on IMPLEMENT-HF](#): Post-hoc analysis shows that Hispanic patients derive less benefits from virtual care platform
10. [Dr. Canonico \(CPC Clinical Research\)](#) finds that the results of the SOLOIST-WHF trial are generalizable to the real-world population
11. [Panel discusses the burdens and unmet needs of HF](#), alongside the treatment potential of SGLT-2s such as sotagliflozin
12. [Dr. Javed Butler \(University of Mississippi\) and Dr. Lee Goldberg \(University of Pennsylvania\)](#) offer insights into rapid sequencing and optimizing GDMT with SGLT-2s
13. [Panel examines gaps between GDMT guidelines and practice](#), use of GDMT in CKD and ‘second line’ therapies

Exhibit Hall

1. [Lexicon](#)
2. [AstraZeneca](#)
3. [Pfizer](#)
4. [Merck](#)
5. [Lilly/BI](#)
6. [Novo Nordisk](#)
7. [Abbott](#)

Previous HFSA Coverage on CCKB

1. [HFSA 2022 Resource Hub](#)
2. [HFSA 2021 Full Report](#)